Across our industry, IoMT will enable us to conduct research in ways that would never previously have been possible.
Whatever the short- and longer-term fallout of COVID-19, organizations will need to come back fighting—with new tools at their disposal and ready to raise their game.
The adoption of accurate non-invasive measures of liver health at the point of care is critical.
Many considerations should not be overlooked.
Throughout 2018, device and diagnostic manufacturers have opportunities to address challenging market trends and turn internal change into ways of increasing business and goodwill from providers who purchase their technology.
Get to know the local government, including the available benefits and incentives first.
The final guidance is part of the agency’s effort to provide better patient access to new devices via stronger and streamlined clinical trials.
The agency is seeking more participation among different genders, ages, races and ethnic groups.
Companies must be aware of the changing clinical trial regulatory environment for devices in China.
The agency’s latest draft guidance is part of its strategy in creating a national evaluation system for medical devices.